Abstract
Many patients with non-Hodgkin (NHL) or Hodgkin lymphoma (HL) relapse or are refractory to initial therapy and require additional options. Bendamustine (B), lenalidomide (L) and rituximab (R) each have activity in this setting. This study was performed to determine the safety of BLR and its optimal phase II dose. Patients with NHL or HL failing standard therapies received B (90 mg/m(2) days 1, 2 every 28 days), and L (escalating from 5 mg 21/28 days) for six cycles, followed by 6 months of L. At the highest dose R 375 mg/m(2) on day one of each cycle was added for patients with B-NHL. Histologies included diffuse large B-cell lymphoma (DLBCL, 11), marginal zone lymphoma (3), HL (2), and one each of transformed follicular lymphoma, Sézary syndrome, Waldenström macroglobulinaemia and mantle cell lymphoma. Neutropenia was the most common grade 3 and 4 toxicity, but no maximum tolerated dose was identified. Of 20 patients, seven responded (35%), including four complete remissions, with five unmaintained responses from 28+ to 37+ months, including 2 DLBCL. BR with 20 mg l at, 21/28 days achieved durable responses; however, in light of its modest activity, and the availability of newer targeted therapies, the future of BLR is uncert...Continue Reading
References
Aug 16, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E WeidmannP S Mitrou
Jan 24, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonUNKNOWN International Harmonization Project on Lymphoma
Jan 10, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jonathan W FriedbergBruce D Cheson
Jul 16, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·K Sue RobinsonBruce D Cheson
Jul 17, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Lei WuJ Blake Bartlett
Feb 20, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D Cheson, Mathias J Rummel
Jul 1, 2009·American Journal of Hematology·Liang ZhangMichael Wang
Jan 14, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·T E WitzigM S Czuczman
Jan 18, 2011·Blood·Jonathan W FriedbergJohn P Leonard
Aug 4, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nathan FowlerBruce D Cheson
Feb 26, 2013·Lancet·Mathias J RummelUNKNOWN Study group indolent Lymphomas (StiL)
Mar 27, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Massimo FedericoMaura Brugiatelli
Apr 18, 2013·Annals of Hematology·F HitzUNKNOWN Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland
May 8, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ken OhmachiMichinori Ogura
May 23, 2013·British Journal of Haematology·Wolfram PönischDietger Niederwieser
Jul 9, 2013·Leukemia & Lymphoma·Giuseppe MeleGianni Quarta
Sep 5, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andre GoyThomas E Witzig
Citations
Nov 26, 2015·Leukemia & Lymphoma·Bruce D ChesonPier Luigi Zinzani
Jul 22, 2015·Expert Review of Anticancer Therapy·Rajshekhar ChakrabortyMorie A Gertz
Mar 29, 2016·British Journal of Haematology·Felicitas HitzUlrich Mey
Apr 22, 2015·British Journal of Haematology·Antonello Pinto, Gaetano Corazzelli
Mar 19, 2016·Blood·Emanuele Zucca, Francesco Bertoni
Mar 22, 2018·Leukemia & Lymphoma·Marc SorigueJuan-Manuel Sancho
Apr 2, 2019·Current Topics in Medicinal Chemistry·Benjamin Diethelm-VarelaFengtian Xue
Oct 18, 2019·Expert Review of Hematology·Lori A LeslieAndre H Goy
Apr 28, 2016·Oncotarget·Arati A InamdarK Stephen Suh
Dec 4, 2016·Hematology·Bertrand Coiffier, Clémentine Sarkozy
Feb 15, 2017·Indian Journal of Hematology & Blood Transfusion : an Official Journal of Indian Society of Hematology and Blood Transfusion·Arjun Datt LawPankaj Malhotra
Jun 24, 2018·Blood Advances·Samuel YamshonJia Ruan
Apr 10, 2021·International Journal of Dermatology·Natalia Rendón-SernaMaria Bermudez-Muñoz